Home
>
References
>
2013
>
A patient with posterior cortical atrophy possesses a novel mutation in the presenilin 1 gene.
A patient with posterior cortical atrophy possesses a novel mutation in the presenilin 1 gene.
Sitek EJ, Narożańska E, Pepłońska B, Filipek S, Barczak A, Styczyńska M, Mlynarczyk K, Brockhuis B, Portelius E, Religa D, Barcikowska M, Sławek J, Zekanowski C.
Journal
|
|
PLoS One
|
Species
|
|
|
Analytes Measured
|
|
,
|
Matrix Tested
|
|
Cerebrospinal fluid (CSF)
|
Year
|
|
2013
|
Volume
|
|
8
|
Page Numbers
|
|
61074
|
Application
|
|
Alzheimers
|
Abstract
Posterior cortical atrophy is a dementia syndrome with symptoms of cortical visual dysfunction, associated with amyloid plaques and neurofibrillary tangles predominantly affecting visual association cortex. Most patients diagnosed with posterior cortical atrophy will finally develop a typical Alzheimer's disease. However, there are a variety of neuropathological processes, which could lead towards a clinical presentation of posterior cortical atrophy. Mutations in the presenilin 1 gene, affecting the function of γ-secretase, are the most common genetic cause of familial, early-onset Alzheimer's disease. Here we present a patient with a clinical diagnosis of posterior cortical atrophy who harbors a novel Presenilin 1 mutation (I211M). In silico analysis predicts that the mutation could influence the interaction between presenilin 1 and presenilin1 enhancer-2 protein, a protein partner within the γ-secretase complex. These findings along with published literature support the inclusion of posterior cortical atrophy on the Alzheimer's disease spectrum.
View Publications
Browse Our Products
Customer Service/Orders
Scientific/Technical Support
Instrument Support
Company Headquarters